Ocular & Corneal Research

TB-500 in Ocular and Corneal Research: A Translational Success Story

Of all the research areas where thymosin beta-4 (Tβ4) has been studied, corneal and ocular surface repair represents the most clinically advanced application. The small molecule size of Tβ4/TB-500, its remarkable safety profile in preclinical testing, and the relative accessibility of the ocular surface for topical drug delivery have made corneal research a natural translational pathway for this peptide class.

The Foundation: Corneal Epithelial Migration

The cornea is covered by a stratified squamous corneal epithelium that undergoes constant renewal from limbal stem cells. Injury to the corneal epithelium (abrasion, chemical burn, surgery, contact lens wear) exposes the underlying stroma and triggers an urgent repair response dependent on epithelial cell migration.

The foundational discoveries by Sosne and colleagues established that Tβ4:

• Stimulates corneal epithelial cell migration in scratch assay models at concentrations as low as 1 ng/mL — among the lowest effective concentrations documented for any Tβ4 effect
• Accelerates corneal epithelial wound closure in in vivo rat corneal abrasion models by 40–50% compared to vehicle controls
• Acts through the LKKTET WH2 domain — both full-length Tβ4 and the LKKTET hexapeptide fragment stimulate corneal migration
• Reduces corneal inflammation (IL-1β, MMP-9) following chemical injury, accelerating return to normal stromal clarity

RGN-259: Clinical Translation and Phase III Trials

The most significant development in Tβ4 ocular research is the clinical-stage compound RGN-259 (RegeneRx Biopharmaceuticals), a sterile ophthalmic solution formulation of Tβ4. RGN-259 has been evaluated in clinical trials for:

Dry Eye Disease (DED)

• Phase III ARISE-3 trial (completed): RGN-259 0.1% ophthalmic solution in patients with moderate-to-severe dry eye disease
• The ARISE-3 trial reported statistically significant improvements in the Ora Calibra Ocular Discomfort & 4-Symptom Score and corneal staining endpoints compared to placebo
• ARISE-3 treated approximately 150 patients per arm with bid/tid dosing for 28 days
• Prior Phase III ARISE-2 trial also showed significant improvements in multiple DED endpoints

Neurotrophic Keratitis

• Neurotrophic keratitis (NK) is a rare corneal condition caused by impaired corneal innervation leading to epithelial breakdown, persistent epithelial defects, and corneal ulceration
• RGN-259 Phase III trials in NK demonstrated complete epithelial healing in a higher proportion of treated patients versus placebo at 6 weeks
• Tβ4's ability to stimulate epithelial migration independently of neurotrophic growth factor signaling (which is deficient in NK) provides a unique mechanism compared to existing treatments

Anti-Inflammatory Effects on the Ocular Surface

Dry eye disease is characterized by ocular surface inflammation mediated by T-cell infiltration, elevated MMP-9, and pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α in tears and conjunctival tissue. TB-500/Tβ4 reduces this inflammatory milieu through:

• Suppression of MMP-9 (tear film MMP-9 is an FDA-cleared biomarker for DED)
• Reduction in goblet cell loss in the conjunctival epithelium
• Decreased HLA-DR+ antigen-presenting cell density on the conjunctival epithelium
• Reduced conjunctival T-cell infiltration

Corneal Nerve Regeneration Research

The cornea is the most densely innervated tissue in the human body, with subbasal nerve plexus density measurable by in vivo confocal microscopy. TB-500 research in corneal nerve injury models has shown:

• Enhanced axonal regrowth into denervated corneal epithelium following neurotomy
• Increased nerve fiber length density (NFLD) measured by IVCM at 4–8 weeks post-injury
• Upregulation of NGF (nerve growth factor) and BDNF in TB-500-treated corneal tissue
• Potential relevance to post-LASIK and post-PRK corneal hypoesthesia recovery

Stromal and Endothelial Research

Beyond epithelial applications, emerging TB-500 research examines:

• Corneal stromal keratocyte activation and collagen synthesis following deep stromal injury
• Corneal endothelial cell (CEC) protection from surgical and UV-induced stress, relevant to endothelial keratoplasty research
• Subconjunctival fibrosis modulation relevant to trabeculectomy (glaucoma surgery) outcomes